Cellivery Therapeutics Inc
KOSDAQ:268600
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Cellivery Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | KR |
| Market Cap | 244.9B KRW |
| Net Margin |
-38%
|
| Country | US |
| Market Cap | 1.3T USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 196.3B USD |
| Net Margin |
14%
|
| Country | US |
| Market Cap | 170.3B USD |
| Net Margin |
18%
|
| Country | KR |
| Market Cap | 66.5T KRW |
| Net Margin |
24%
|
| Country | CH |
| Market Cap | 37.6B CHF |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 38.5B USD |
| Net Margin |
22%
|
| Country | US |
| Market Cap | 36.7B USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 26.4B USD |
| Net Margin |
21%
|
| Country | US |
| Market Cap | 23B USD |
| Net Margin |
17%
|
| Country | US |
| Market Cap | 22.3B USD |
| Net Margin |
-36%
|
Cellivery Therapeutics Inc
Glance View
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Cellivery Therapeutics Inc's most recent financial statements, the company has Net Margin of -38.5%.
You don't have any saved screeners yet
